(CYTK) Cytokinetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23282W6057

Cardiac Activator, Cardiac Inhibitor, Skeletal Activator

Biotechnology
Market Cap in USD: 7,547m
IPO / Inception: 2004-04-29
Return 12m vs S&P 500: 10.8%

EPS (Earnings per Share)

EPS (Earnings per Share) of CYTK over the last years for every Quarter: "2020-12": -0.62, "2021-03": -0.66, "2021-06": -0.86, "2021-09": -0.95, "2021-12": -0.36, "2022-03": -1.02, "2022-06": -0.23, "2022-09": -1.52, "2022-12": -1.45, "2023-03": -1.38, "2023-06": -1.34, "2023-09": -1.35, "2023-12": -1.38, "2024-03": -1.33, "2024-06": -1.31, "2024-09": -1.36, "2024-12": -1.26, "2025-03": -1.36, "2025-06": -1.12, "2025-09": -2.55, "2025-12": 0,
EPS CAGR: 13.59%
EPS Trend: -2.9%
Last SUE: 3.77
Qual. Beats: 1

Revenue

Revenue of CYTK over the last years for every Quarter: 2020-12: 6.722, 2021-03: 6.548, 2021-06: 2.843, 2021-09: 5.437, 2021-12: 55.6, 2022-03: 1.148, 2022-06: 88.968, 2022-09: 2.515, 2022-12: 1.957, 2023-03: 4.613, 2023-06: 0.867, 2023-09: 0.378, 2023-12: 1.672, 2024-03: 0.835, 2024-06: 0.249, 2024-09: 0.463, 2024-12: 16.927, 2025-03: 1.579, 2025-06: 66.769, 2025-09: 1.936, 2025-12: null,
Rev. CAGR: -59.15%
Rev. Trend: -18.1%
Last SUE: -0.18
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 54.2%
Value at Risk 5%th 75.9%
Relative Tail Risk -14.87%
Reward TTM
Sharpe Ratio 0.66
Alpha 15.63
CAGR/Max DD 0.19
Character TTM
Hurst Exponent 0.489
Beta 0.601
Beta Downside 0.497
Drawdowns 3y
Max DD 72.39%
Mean DD 40.55%
Median DD 43.23%

Description: CYTK Cytokinetics January 08, 2026

Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biopharma focused on small-molecule modulators of muscle contractility. Its pipeline includes the cardiac myosin activator omecamtiv mecarbil (Phase III heart-failure trial), the fast skeletal muscle troponin activator CK-089 (Phase I), the cardiac myosin inhibitor CK-586 (Phase II), and aficamten, an oral cardiac myosin inhibitor now in Phase III for hypertrophic cardiomyopathy (HCM). The company also holds a strategic alliance with Ji Xing Pharmaceuticals for aficamten’s development and commercialization in Japan.

Key quantitative context (as of FY 2023): cash and short-term investments of roughly $380 million, giving a runway of ~2 years at current burn rates; market capitalization around $1.1 billion, reflecting a price-to-sales multiple of ~30× the modest 2022 revenue of $35 million. The U.S. heart-failure therapeutic market is projected to exceed $5 billion by 2028, while HCM prevalence (≈0.2 % of adults) supports a niche market valued at $1–2 billion, both of which are driving investor interest in muscle-targeted therapeutics. Biotech sector R&D intensity remains high, with average R&D spend ≈25 % of revenue, underscoring the importance of cash efficiency for CYTK’s upcoming trial readouts.

For a deeper, data-driven look at CYTK’s valuation dynamics, you might find ValueRay’s analytical platform worth exploring.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-751.9m TTM) > 0 and > 6% of Revenue (6% = 5.23m TTM)
FCFTA -0.32 (>2.0%) and ΔFCFTA -3.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 957.7% (prev 28.2k%; Δ -27.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.30 (>3.0%) and CFO -432.9m > Net Income -751.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 6.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (120.0m) change vs 12m ago 1.95% (target <= -2.0% for YES)
Gross Margin -127.5% (prev -10.2k%; Δ 10.0kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 6.07% (prev 0.22%; Δ 5.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -6.82 (EBITDA TTM -646.2m / Interest Expense TTM 96.1m) >= 6 (WARN >= 3)

Altman Z'' -8.52

(A) 0.58 = (Total Current Assets 977.3m - Total Current Liabilities 142.1m) / Total Assets 1.44b
(B) -2.30 = Retained Earnings (Balance) -3.30b / Total Assets 1.44b
warn (B) unusual magnitude: -2.30 — check mapping/units
(C) -0.46 = EBIT TTM -655.8m / Avg Total Assets 1.44b
(D) -1.69 = Book Value of Equity -3.30b / Total Liabilities 1.96b
Total Rating: -8.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.09

1. Piotroski 0.0pt
2. FCF Yield -5.83%
3. FCF Margin data missing
4. Debt/Equity -2.30
5. Debt/Ebitda -1.50
7. RoE 232.9%
8. Rev. Trend -18.06%
9. EPS Trend -2.87%

What is the price of CYTK shares?

As of January 12, 2026, the stock is trading at USD 62.51 with a total of 2,482,385 shares traded.
Over the past week, the price has changed by +2.04%, over one month by +2.86%, over three months by +4.90% and over the past year by +33.83%.

Is CYTK a buy, sell or hold?

Cytokinetics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CYTK.
  • Strong Buy: 9
  • Buy: 9
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CYTK price?

Issuer Target Up/Down from current
Wallstreet Target Price 86.6 38.5%
Analysts Target Price 86.6 38.5%
ValueRay Target Price 68.8 10%

CYTK Fundamental Data Overview January 05, 2026

P/S = 86.542
P/B = 60.3093
P/EG = -0.42
Beta = 0.589
Revenue TTM = 87.2m USD
EBIT TTM = -655.8m USD
EBITDA TTM = -646.2m USD
Long Term Debt = 1.05b USD (from longTermDebt, last quarter)
Short Term Debt = 37.9m USD (from shortTermDebt, last quarter)
Debt = 1.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.3m USD (from netDebt column, last quarter)
Enterprise Value = 7.78b USD (7.55b + Debt 1.20b - CCE 962.5m)
Interest Coverage Ratio = -6.82 (Ebit TTM -655.8m / Interest Expense TTM 96.1m)
EV/FCF = -17.16x (Enterprise Value 7.78b / FCF TTM -453.4m)
FCF Yield = -5.83% (FCF TTM -453.4m / Enterprise Value 7.78b)
FCF Margin = -519.9% (FCF TTM -453.4m / Revenue TTM 87.2m)
Net Margin = -862.2% (Net Income TTM -751.9m / Revenue TTM 87.2m)
Gross Margin = -127.5% ((Revenue TTM 87.2m - Cost of Revenue TTM 198.4m) / Revenue TTM)
Gross Margin QoQ = -38.38% (prev 96.58%)
Tobins Q-Ratio = 5.42 (Enterprise Value 7.78b / Total Assets 1.44b)
Interest Expense / Debt = 2.20% (Interest Expense 26.3m / Debt 1.20b)
Taxrate = 21.0% (US default 21%)
NOPAT = -518.1m (EBIT -655.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.88 (Total Current Assets 977.3m / Total Current Liabilities 142.1m)
Debt / Equity = -2.30 (negative equity) (Debt 1.20b / totalStockholderEquity, last quarter -521.1m)
Debt / EBITDA = -1.50 (negative EBITDA) (Net Debt 968.3m / EBITDA -646.2m)
Debt / FCF = -2.14 (negative FCF - burning cash) (Net Debt 968.3m / FCF TTM -453.4m)
Total Stockholder Equity = -322.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.35% (Net Income -751.9m / Total Assets 1.44b)
RoE = 232.9% (negative equity) (Net Income TTM -751.9m / Total Stockholder Equity -322.9m)
RoCE = -90.41% (EBIT -655.8m / Capital Employed (Equity -322.9m + L.T.Debt 1.05b))
RoIC = -114.1% (out of range, set to none) (NOPAT -518.1m / Invested Capital 454.2m)
WACC = 7.26% (E(7.55b)/V(8.74b) * Re(8.13%) + D(1.20b)/V(8.74b) * Rd(2.20%) * (1-Tc(0.21)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.05%
Fair Price DCF = unknown (Cash Flow -453.4m)
EPS Correlation: -2.87 | EPS CAGR: 13.59% | SUE: 3.77 | # QB: 1
Revenue Correlation: -18.06 | Revenue CAGR: -59.15% | SUE: -0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.53 | Chg30d=+0.052 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-5.86 | Chg30d=+0.106 | Revisions Net=-1 | Growth EPS=+3.7% | Growth Revenue=+76.7%

Additional Sources for CYTK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle